The food distributor's shares appear undervalued and that presents investors with opportunity to profit by buying its shares or initiating option positions.
Oncology concern Exelixis and biopharma Ardelyx offer reasons to believe their shares should rise in the months ahead.
The charts of U.S. Steel, Freeport-McMoRan and DuPont suggest that the surge in their shares may have just begun.
Participants largely have ignored the risks to stocks posed by the makeup of the government and the lingering coronavirus, and that could be costly.
It's hard to find value in a picked-over market trading at all-time highs, which leaves this participant building his cash position.
The virtual work force, online shopping and a love of pets are not going to go away even after the coronavirus abates.
It doesn't look like a good idea at present based on the Chinese e-commerce giant's technical signals.
Look for a weaker dollar to perk up the energy sector, the exodus from big cities to continue, and gun and ammo sales to remain strong
The former name is technically overbought but offers reasons to expect it to grow, while the latter should benefit from the Covid-19 vaccines.
The consistent annual dividend increases by this quartet even during bad times make them good income-investing bets going forward.